Advances in Antitumor Drugs

Chemotherapy is a category of cancer treatment that uses chemical substances, especially one or more antitumor drugs that are given as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent which almost always involves combinations of antitumor drugs, or it may aim to prolong life or to reduce symptoms. By common usage, the term chemotherapy has come to connote the use of rather non-specific intracellular poisons, especially related to inhibiting the process of cell division known as mitosis, and generally excludes agents that more selectively block extracellular growth signals. Importantly, the use of antitumor drugs constitutes “systemic therapy” for cancer in that they are introduced into the blood stream and are therefore in principle able to address cancer at any anatomic location in the body.


In the present book, twelve typical literatures about antitumor drugs published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, oncology, chemotherapy, ect. We hope this book can demonstrate advances in antitumor drugs as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    Aloperine Executes Antitumor Effects against Multiple Myeloma through Dual Apoptotic Mechanisms
  • Chapter 2
    Mek Inhibition Results in Marked Antitumor Activity against Metastatic Melanoma Patient-Derived Melanospheres and in Melanosphere-Generated Xenografts
  • Chapter 3
    Antitumor Activity of Doxorubicin-Loaded Carbon Nanotubes Incorporated Poly (Lactic-Co-Glycolic Acid) Electrospun Composite Nanofibers
  • Chapter 4
    Antitumor and Antimetastatic Activities of Chloroform Extract of Medicinal Mushroom Cordyceps Taii in Mouse Models
  • Chapter 5
    Antitumor Effects of Cecropin B-LHRH’ on Drug-Resistant Ovarian and Endometrial Cancer Cells
  • Chapter 6
    Combination of Autophagy Inducer Rapamycin and Oncolytic Adenovirus Improves Antitumor Effect in Cancer Cells
  • Chapter 7
    Combined PD-1 Blockade and GITR Triggering Induce a Potent Antitumor Immunity in Murine Cancer Models and Synergizes with Chemotherapeutic Drugs
  • Chapter 8
    Entrapment of an EGFR Inhibitor into Nanostructured Lipid Carriers (NLC) Improves Its Antitumor Activity against Human Hepatocarcinoma Cells
  • Chapter 9
    Herbal Compound Triptolide Synergistically Enhanced Antitumor Activity of Amino-Terminal Fragment of Urokinase
  • Chapter 10
    Intermittent High Dose Proton Pump Inhibitor Enhances the Antitumor Effects of Chemotherapy in Metastatic Breast Cancer
  • Chapter 11
    The Combination of Sorafenib and Everolimus Shows Antitumor Activity in Preclinical Models of Malignant Pleural Mesothelioma
  • Chapter 12
    Targeting Endothelial Cell Metabolism for Cardio-Protection from the Toxicity of Antitumor Agents
Readership: Students, academics, teachers and other people attending or interested in Advances in Antitumor Drugs
He Wang
Department of Oncology, The Second Affiliated Hospital of Guangzhou Medical University, College of Pharmaceutics Science, Guangzhou Medical University, Guangzhou, China

Xiaoyong Li
Department of Gynecology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Pei-Hsin Cheng
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, USA

Maria Luisa Bondì
Istituto per lo Studio dei Materiali Nanostrutturati, U.O.S. Palermo, Consiglio Nazionale delle Ricerche, Palermo, Italy

Bi-Yun Wang
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

Ymera Pignochino
Division of Medical Oncology, IRCCS-Institute for Cancer Research and Treatment, Candiolo, Italy

and more...
Copyright © 2006-2022 Scientific Research Publishing Inc. All Rights Reserved.